Platform & Science

Activity of SY-5609 in Preclinical Models of Colorectal Cancer

Posted By Graeme Hodgson, Ph.D., Senior Director, Translational Medicine

May 29, 2020

By Graeme Hodgson, Ph.D., Senior Director, Translational Medicine

CDK7 is a key regulator of 2 cellular processes that are fundamental to cancer development, transcription and cell cycle control. Syros is developing SY-5609 as a highly selective and potent oral CDK7 inhibitor for the treatment of many kinds of solid tumors. Here Syros senior director of Translations Medicine, Graeme Hodgson, Ph.D., discusses preclinical data and rationale for investigating SY-5609 in colorectal cancer.

Additional Information »